The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.
BrainsWay Ltd.
BWAY · Nasdaq · USD · Market cap $569M · 129 employees
BrainsWay Ltd.
PASS · Titan Ethical · score 70.0At the last full screen
2026-09-18
Screened 2026-09-18 · the tape above runs as of 23:00 UTC · 21 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 13.61 against the desk's fair-value range, base estimate 15.07, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
BrainsWay Ltd. holds its Markdown at $13.61. The statistical read favours the sellers, held for 9 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 9 days |
| Price at the screen | $13.61 |
| Valuation | 61.52 trailing · 27.93 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.08 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1.07% | Below 33% | Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 10.62% | Below 33% | Cash held in interest-bearing accounts and securities is 10.6% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 11% discount to our $15.07 fair value, moderate competitive moat, 35.40% revenue growth.
Fair value range in USD, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. A 10.8% margin of safety to the base estimate.
Third-party analyst targets: 3 covering, consensus Strong Buy. The average target sits +40% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a moderate moat and 16% profit margins. It trades close to our $15.07 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | 27.9xfairly priced for its growth rate |
| Trailing P/E | 61.5xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.23 |
| EPS, forward | 0.51 |
| Revenue growth | +35.4%strong top-line growth |
| Profit margin | 15.6%healthy profit margins |
| Return on equity | 12.8%a solid return on shareholder capital |
| FCF yield | -1.08% |
| Debt to equity | 0.09minimal debt: a conservative balance sheet |
| Current ratio | 3.59comfortably covers its short-term bills |
| Beta | 0.08barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 7.14 - 17.40 |
| Moat | MODERATE |
| Market cap | $569M |
| Employees | 129 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBWAY trades on Nasdaq (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 49% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 148%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (3 analysts) rates it strong buy, with a mean price target of $16.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- BrainsWay’s (BWAY) Growth Streak Just Got Harder To Ignore Insider Monkey · 11d ago
- Are Options Traders Betting on a Big Move in Brainsway Stock? Zacks · 12d ago
- Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High? Zacks · 26d ago
- Brainsway (BWAY) Upgraded to Buy: Here's Why Zacks · 17 Aug 2026
- Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Zacks · 17 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $16.73 | -15.0% | · | $850 | -15.0% |
| 2 months | $13.92 | +2.2% | · | $1,022 | +2.2% |
| 3 months | $13.74 | +3.5% | · | $1,035 | +3.5% |
| 6 months | $8.71 | +63.3% | · | $1,633 | +63.3% |
| 1 year | $5.73 | +148.3% | · | $2,483 | +148.3% |
| 2 years | $3.33 | +327.2% | · | $4,272 | +327.2% |
| 3 years | $1.10 | +1,199.1% | · | $12,991 | +1,199.1% |
| 5 years | $5.78 | +145.9% | · | $2,459 | +145.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BWAY does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.